{{Drugbox
| verifiedrevid = 451605875
| IUPAC_name = (1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methylnaphthalen-1-ylmethanone
| image = JWH-193_structure.png
| width = 220

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 133438-58-1
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 10250276
| UNII = WB1TIJ1IO9
| UNII_Ref = {{fdacite|correct|FDA}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID      = 8425762


<!--Chemical data-->
| C=26 | H=26 | N=2 | O=2 
| molecular_weight = 398.496 g/mol
| smiles = c3cccc1c3c(ccc1C)C(=O)c5c2ccccc2n(c5)CCN4CCOCC4
| StdInChI          = 1S/C26H26N2O2/c1-19-10-11-23(21-7-3-2-6-20(19)21)26(29)24-18-28(25-9-5-4-8-22(24)25)13-12-27-14-16-30-17-15-27/h2-11,18H,12-17H2,1H3
| StdInChIKey       = ICKWPPYMDARCKJ-UHFFFAOYSA-N
}}

'''JWH-193''' is a drug from the [[aminoalkylindole]] family which acts as a [[cannabinoid]] [[Receptor (biochemistry)|receptor]] [[agonist]]. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-193 has a [[Dissociation constant|binding affinity]] at the CB<sub>1</sub> receptor of 6nM, binding around seven times more tightly than the parent compound [[JWH-200]],<ref>Huffman JW, Padgett LW. Recent Developments in the Medicinal Chemistry of Cannabimimetic Indoles, Pyrroles and Indenes. ''Current Medicinal Chemistry'', 2005; 12: 1395-1411.</ref> though with closer to twice the potency of JWH-200 in activity tests. A structural isomer of JWH-193 with the methyl group on the indole ring instead of the naphthoyl ring, was also found to be of similarly increased potency over JWH-200.<ref name="pmid7636873">{{cite journal  |vauthors=Eissenstat MA, etal |title=Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics |journal=Journal of Medicinal Chemistry |volume=38 |issue=16 |pages=3094–105 |date=August 1995 |pmid=7636873 |doi= 10.1021/jm00016a013 }}</ref><ref name="pmid9804691">{{cite journal  |vauthors=Shim JY, etal |title=Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis |journal=Journal of Medicinal Chemistry |volume=41 |issue=23 |pages=4521–32 |date=November 1998 |pmid=9804691 |doi=10.1021/jm980305c }}</ref>

[[Image:6-methyl-JWH-200.png|180px|thumb|left|6-Methyl-JWH-200]]{{clear-left}}

==See also==
* [[JWH-122]]
* [[JWH-198]]

==References==
{{Reflist}}

{{Cannabinoids}}

[[Category:JWH cannabinoids]]
[[Category:Aminoalkylindoles]]
[[Category:Naphthoylindoles]]
[[Category:Morpholines]]
[[Category:Designer drugs]]


{{cannabinoid-stub}}